Drug Class: Immunotherapy

Vaccines: Survivin

Treatment given for recurrence occurring at any time after last platinum-based treatment

Objective Response Rate (%)

Percentage of patients whose tumors shrink or go away after treatment

Progression Free Survival (months)

Median length of time before the cancer comes back or gets worse

3 Prior Therapies

Vaccine: Tumor Associated Antigens

Platinum-Sensitive (Pt-S): Treatment given for recurrence occurring 6 months or more after last platinum-based treatment

Progression Free Survival (months)

Median length of time before the cancer comes back or gets worse

Overall Survival (months)

The length of time where half the patients in the study are still alive

1 Prior Therapy

Vaccines: NY-ESO-1

Platinum-Resistant/Refractory (Pt-R/Rf): Treatment given for recurrence occurring less than 6 months after last platinum-based treatment or for progression during last platinum-based treatment

For more detailed information, please click on the clinical trial ID number.

Trial ID # Phase Drugs Clinical Trial Title Key Conclusion and Results
Drugs in Clinical Development
NCT00887796 I Decitabine, Liposomal doxorubicin, NY-ESO-1 protein / MIS416 vaccine A Phase I Clinical Trial of NY-ESO-1 Protein Immunization in Combination With 5-AZA-2'-Deoxycytidine (Decitabine) in Patients Receiving Liposomal Doxorubicin for Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma

Encouraging anti-tumor activity of NY-ESO-1 vaccine+liposomal doxorubicin combination

ORR: 10% (n=10)
DCR: 60% (n=10)

pub 2014

Vaccines: Survivin

Treatment given for recurrence occurring at any time after last platinum-based treatment

For more detailed information, please click on the clinical trial ID number.

Trial ID # Phase Drugs Clinical Trial Title Key Conclusion and Results
Drugs in Clinical Development
NCT02785250; DeCidE1 Ib/II Cyclophosphamide, Epacadostat, Maveropepimut-S A Phase 1b/2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide and Epacadostat (INCB024360) in Patients With Recurrent Ovarian Cancer

Encouraging anti-tumor activity of immunotherapy combination with limited side effects

ORR: 26.3%
DCR: 78.9%
PFS: 4.5 months
CBR: 37%
OS: 19.9 months

Patients with Baseline Tumor Burden (BTB) <5 cm:
CBR: 55% (n=11)

abs Jun 2019 and poster, abs May 2020 and poster, pub 2023

Vaccine: TGFbeta

Maintenance after first-line therapy: Treatment to prevent relapse after complete or partial response to therapy

For more detailed information, please click on the clinical trial ID number.

Trial ID # Phase Drugs Clinical Trial Title Key Conclusion and Results
Drugs in Clinical Development
NCT01309230 II Gemogenovatucel-T Open-label Phase II Trial of Adjuvant bishRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage III/IV Ovarian Cancer

FANG vaccine shows encouraging anti-tumor activity and increased RFS with remarkable safety

FANG vs Placebo:

RFS (from time of procurement, mean/median):
27.5/20.1 (n=31) vs 16.0/12.6 (n=11) months

pub 2016
NCT02346747; VITAL II Gemogenovatucel-T A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects With Stage IIIb-IV Ovarian Cancer in Clinical Complete Response Following Surgery and Primary Chemotherapy

Vigil immunotherapy as maintenance after first-line therapy in stage III–IV ovarian cancer is well tolerated and shows clinical benefit, particularly for BRCA WT and HRP patients that have high levels of CD39 RNA

VIGIL vs Placebo:
RFS (from time of randomization): 11.5 vs 8.4 months

BRCA WT patients:
RFS (from time of randomization): 12.7 vs 8.0 months*
OS: NR vs 41.4 months*

HRP patients:
RFS (from time of randomization): 10.6 vs 5.7 months*
OS: NR vs 26.9 months*

HRP and CD39 RNA levels above median:
RFS (from time of randomization): 21.1 vs 5.6 months*
OS: NR vs 27 months*

pub 2020, pub 2021, pub 2022
*Statistically significant result

Vaccine: Tumor Associated Antigens

First-line treatment with/without extended (maintenance) treatment

For more detailed information, please click on the clinical trial ID number.

Trial ID # Phase Drugs Clinical Trial Title Key Conclusion and Results
Drugs in Clinical Development
NCT02107937; SOVO1 II DCVAC/OvCa A Randomized, Open-label, Three-arm, Multi-center Phase II Trial of Addition of DCVAC/OvCa to First Line Standard Chemotherapy in Women With Newly Diagnosed Epithelial Ovarian Carcinoma

DCVAC/OvCa sequential to chemo is associated with a statistically significant improvement in PFS in patients undergoing first-line treatment

DCVAC sequential to chemo vs chemo alone:
PFS: NR vs 21.4 months*

pub 2022
*Statistically significant result

Platinum-Sensitive (Pt-S): Treatment given for recurrence occurring 6 months or more after last platinum-based treatment

For more detailed information, please click on the clinical trial ID number.

Trial ID # Phase Drugs Clinical Trial Title Key Conclusion and Results
Drugs in Clinical Development
NCT02107950; SOVO2 II Carboplatin, DCVAC/OvCa, Gemcitabine A Randomized, Open-label, Parallel Group, Multi-center Phase II Clinical Trial DCVAC/OvCa Added to Standard Chemotherapy in Women With Relapsed Platinum Sensitive Epithelial Ovarian Carcinoma

Significantly prolonged OS with addition of DCVAC/OvCa to carboplatin+gemcitabine

Carbo+Gem+DCVAC/OvCa vs Carbo+Gem:

PFS: 11.3 vs 10.1 months
OS: 35.5 vs. 22.1 months*

pub 2021
*Statistically significant result

< Return to Drug Classes

< Return to Clinical Trial Results Homepage